个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment.

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Zhao Bingkun[1] ; Qin Shanshan[1] ; Chai Li[1] ; Lu Gaixia[1] ; Yang Yuanyou[2] ; Cai Huawei[3] ; Yuan Xueyu[1] ; Fan Suyun[1,*1] ; Huang Qingqing[1,*1] ; Yu Fei[1,*1] ;
机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China [2]Key Laboratory of Radiation Physics and Technology, Ministry of Education, Institute of Nuclear Science and Technology, Sichuan University, Chengdu 610064, PR China [3]Department of Nuclear Medicine, Sichuan Huaxi Hospital, Sichuan University, Chengdu 610000, PR China
出处：
DOI： 10.1016/j.bmc.2018.01.023
ISSN：

关键词： Astatine-211 Octreotide Alpha therapy Non-small cell lung cancer

摘要：
Octreotide is a somatostatin (SST) analogue currently used in the treatment of neuroendocrine tumors (NETs) with high binding affinity for the somatostatin receptor-2 (SSTR2) that is also overexpressed in non-small cell lung cancer cell (NSCLC). Alpha-particle-emitting astatine-211 (211At) is a promising radionuclide with appropriate physical and chemical properties for use in targeted anticancer therapies. To obtain an additional pharmacological agent for the treatment of NSCLC, we present the first investigation of the possible use of 211At-labeled octreotide as a potential alpha-radionuclide therapeutic agent for NSCLC treatment. 211At-SPC-octreotide exhibited observable higher uptake in lung, spleen, stomach and intestines than in other tissues. Through histological examination, 211At-SPC-octreotide demonstrated much more lethal effect than control groups (PBS, octreotide and free 211At). These promising preclinical results suggested that 211At labeled octreotide deserved to be further developed as a new anticancer agent for NSCLC. Copyright © 2018 Elsevier Ltd. All rights reserved.

基金：
National Natural Science Foundation of China (81671736, 81301993 and 21371124), Science and Technology Commission of Shanghai Municipality (14441901300 and 14DZ1940606).
语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2018]版：
大类 | 3 区 医学
小类 | 3 区 生化与分子生物学 3 区 药物化学 3 区 有机化学
最新[2023]版：
大类 | 3 区 医学
小类 | 2 区 有机化学 3 区 生化与分子生物学 3 区 药物化学
第一作者：
第一作者机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China
共同第一作者：
通讯作者：
通讯机构： [1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, Shanghai 200072, PR China [*1]Department of Nuclear Medicine, Shanghai 10th People’s Hospital, Tongji University School of Medicine, 301 Middle Yanchang Road, Shanghai 200072, PR China
推荐引用方式(GB/T 7714)：
Zhao Bingkun,Qin Shanshan,Chai Li,et al.Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment.[J].Bioorganic & medicinal chemistry.2018,26(5):1086-1091.doi:10.1016/j.bmc.2018.01.023.
APA：
Zhao Bingkun,Qin Shanshan,Chai Li,Lu Gaixia,Yang Yuanyou...&Yu Fei.(2018).Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment..Bioorganic & medicinal chemistry,26,(5)
MLA：
Zhao Bingkun,et al."Evaluation of astatine-211-labeled octreotide as a potential radiotherapeutic agent for NSCLC treatment.".Bioorganic & medicinal chemistry 26..5(2018):1086-1091

相关文献

[1]Neoadjuvant and Adjuvant Therapy for Non-Small Cell Lung Cancer [2]Effective Treatment of SSTR2-Positive Small Cell Lung Cancer Using 211At-Containing Targeted α-Particle Therapy Agent Which Promotes Endogenous Antitumor Immune Response [3]Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer [4]RSPH14 regulates the proliferation, cell cycle progression, and apoptosis of non-small cell lung cancer cells [5]Cell-type-specific alternative polyadenylation promotes oncogenic gene expression in non-small cell lung cancer progression [6]Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer [7]Expert consensus on perioperative treatment for non-small cell lung cancer [8]Neoadjuvant strategy for stage IIIA-N2 non-small cell lung cancer: chemoradiation or chemotherapy alone? [9]Radiation Dose Painting with Concurrent Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer [10]The Effect of immunotherapy on oligometastatic non-small cell lung cancer patients by sites of metastasis

资源点击量：43390 今日访问量：1 总访问量：3121 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号